MA52226B1 - Nouveaux analogues de glp-1 - Google Patents

Nouveaux analogues de glp-1

Info

Publication number
MA52226B1
MA52226B1 MA52226A MA52226A MA52226B1 MA 52226 B1 MA52226 B1 MA 52226B1 MA 52226 A MA52226 A MA 52226A MA 52226 A MA52226 A MA 52226A MA 52226 B1 MA52226 B1 MA 52226B1
Authority
MA
Morocco
Prior art keywords
analogs
present
glp
analogues
action
Prior art date
Application number
MA52226A
Other languages
English (en)
Other versions
MA52226A (fr
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Priority claimed from PCT/IB2019/052835 external-priority patent/WO2019193576A1/fr
Publication of MA52226A publication Critical patent/MA52226A/fr
Publication of MA52226B1 publication Critical patent/MA52226B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux analogues de peptide-1 de type glucagon (glp-1) (7-37) ayant une séquence d'acides aminés avec leu ou ile au niveau de l'extrémité c-terminale. Les nouveaux analogues sont des agonistes puissants de glp-1 ayant un effet indésirable réduit et une durée d'action améliorée. La présente invention concerne en outre des dérivés acylés des nouveaux analogues qui ont en outre une puissance et une durée d'action améliorées et sont appropriés pour une administration par voie orale. Les analogues selon la présente invention peuvent être utiles dans le traitement du diabète et de l'obésité.
MA52226A 2018-04-05 2019-04-05 Nouveaux analogues de glp-1 MA52226B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
PCT/IB2019/052835 WO2019193576A1 (fr) 2018-04-05 2019-04-05 Nouveaux analogues de glp-1

Publications (2)

Publication Number Publication Date
MA52226A MA52226A (fr) 2021-02-17
MA52226B1 true MA52226B1 (fr) 2022-08-31

Family

ID=83280018

Family Applications (2)

Application Number Title Priority Date Filing Date
MA59093A MA59093B1 (fr) 2018-04-05 2019-04-05 Nouveaux analogues de glp-1
MA52226A MA52226B1 (fr) 2018-04-05 2019-04-05 Nouveaux analogues de glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA59093A MA59093B1 (fr) 2018-04-05 2019-04-05 Nouveaux analogues de glp-1

Country Status (1)

Country Link
MA (2) MA59093B1 (fr)

Also Published As

Publication number Publication date
MA52226A (fr) 2021-02-17
MA59093B1 (fr) 2024-05-31

Similar Documents

Publication Publication Date Title
MA31242B1 (fr) Co-agonistes des recepteurs du glucagon/glp-1
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
AR104932A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
ZA202306729B (en) Novel glp-1 analogues
CN113144178B (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
RU2019100887A (ru) Композиции антитела и белка
PE20142332A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
RU2013148537A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
MY133954A (en) Compositions and methods of treatment for conditions responsive to testosterone elevation.
JP2002526454A5 (fr)
RU2015101826A (ru) Применение долгодействующих пептидов glp-1
EA200100872A1 (ru) Композиция валдекоксиба
RU2017146657A (ru) Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона
MA44206A (fr) Comprimé orodispersible comprenant estetrol
CA2593201C (fr) Methode de traitement ou de prevention de la deterioration, de blessure ou de dommage tissulaire engendre par une maladie neuro-degenerative, degenerative musculaire ou degenerative neuro-musculaire ou permettant de restaurer un tissu altere par une telle maladie
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
RU2020112302A (ru) Соединения для уменьшения вязкости биологических композиций
EA202091464A1 (ru) Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MA52226B1 (fr) Nouveaux analogues de glp-1
US20180193423A1 (en) Peptides comprising non-natural amino acids and methods of making and using the same
Sultana et al. The kynurenine pathway in HIV, frailty and inflammaging
CA2884386C (fr) Traitement de l'arthrose par les hormones incretines ou leurs analogues
US10105442B2 (en) Treatment of diabetes type 1 using GLP-1 and anti-IL-21
EP2951200A1 (fr) Composés agonistes du récepteur kiss1 et leur utilisation pour induire l'ovulation chez les mammifères
EA202092017A1 (ru) Новые аналоги glp-1